Table 2 Antiproliferative activities of selected paclitaxel-benzoxazoles hybrids against MDA-MB-231.
Compd. | Percentage of antiproliferation against MDA-MB-231 | IC50 (µM) | ||||
|---|---|---|---|---|---|---|
3.125 µM | 6.25 µM | 12.5 µM | 25 µM | 50 µM | ||
7a | 6.8 ± 0.6 | 12.7 ± 0.3 | 23.1 ± 0.8 | 43.7 ± 0.5 | 80.2 ± 0.8 | 25.6 ± 0.9 |
7b | 2.2 ± 0.4 | 6.1 ± 0.8 | 13.2 ± 0.4 | 20.7 ± 0.5 | 66.4 ± 0.6 | 38.8 ± 1.2 |
7c | 6.9 ± 1.4 | 18.3 ± 1.0 | 22.9 ± 0.9 | 32.1 ± 0.5 | 55.4 ± 0.6 | 44.9 ± 1.7 |
7d | 3.4 ± 0.4 | 6.3 ± 1.1 | 15.0 ± 0.6 | 25.8 ± 0.7 | 66.5 ± 0.5 | 37.4 ± 2.3 |
7e | 8.4 ± 0.7 | 10.3 ± 0.9 | 21.2 ± 1.4 | 38.3 ± 2.3 | 78.4 ± 1.8 | 28.1 ± 1.9 |
7h | 5.9 ± 0.8 | 7.8 ± 0.5 | 16.0 ± 0.6 | 32.6 ± 0.4 | 72.7 ± 0.5 | 35.5 ± 0.8 |
7i | 5.8 ± 1.5 | 16.8 ± 1.0 | 21.8 ± 1.8 | 30.3 ± 1.9 | 54.8 ± 0.8 | 48.4 ± 2.4 |
7k | 4.1 ± 0.6 | 10.0 ± 0.9 | 15.5 ± 0.6 | 32.5 ± 1.3 | 86.0 ± 1.0 | 29.5 ± 1.1 |
7l | 15.7 ± 1.1 | 19.1 ± 0.4 | 30.5 ± 2.1 | 41.5 ± 1.2 | 56.3 ± 1.9 | 37.2 ± 1.6 |
7A | 16.8 ± 0.9 | 18.1 ± 2.3 | 20.0 ± 1.8 | 62.5 ± 0.3 | 75.0 ± 2.1 | 21.7 ± 0.8 |
7B | 12.5 ± 0.7 | 15.1 ± 1.2 | 18.6 ± 1.8 | 31.7 ± 1.5 | 70.5 ± 1.7 | 33.2 ± 1.3 |
7D | 8.0 ± 1.1 | 12.6 ± 0.7 | 19.3 ± 1.4 | 41.0 ± 2.0 | 70.2 ± 0.9 | 31.2 ± 1.5 |
7E | 17.7 ± 1.2 | 21.6 ± 0.5 | 31.0 ± 0.4 | 46.8 ± 0.5 | 65.4 ± 0.8 | 27.8 ± 0.6 |
Paclitaxel | – | – | – | – | – | 0.32 ± 0.08 |
